Expert Commentary: Cytokine inhibitors have a low prevalence of SARS-CoV-2 seroconversion
Read expert commentary from IPC Board Member Johann Gudjonsson MD, PhD, discussing a recent study on the prevalence of anti-SARS-CoV-2 immunoglobulin G (IgG) in patients with chronic immune-mediated inflammatory diseases on cytokine-blocking treatments in this expert commentary.
Expert Commentary: Genetic studies suggest that inflammatory skin diseases increase the risk of COVID-19
IPC Councilor Francesca Capon, PhD, discusses a recent publication that suggests that diseases such as psoriasis and atopic dermatitis increase the risk of COVID-19 by approximately 50%.
Genital psoriasis is a frequently overlooked manifestation of psoriasis. The static Physician’s Global Assessment of Genitalia (sPGA-G) scale was created for the assessment of genital psoriasis severity that accounts for the erythematous clinical presentation of genital psoriasis.
IPC has the sPGA-G scale along with the other most commonly used measurement tools for psoriasis management.
Challenging cases in psoriasis: A focus on COVID-19, biologics and adverse events
Reunión Anual De Dermatólogos Latinoamericanos (RADLA)
Saturday, April 17, 2021 | 5:00 pm - 6:30 pm PYT (virtual, live event)
Program chairs: Ricardo Romiti, Brazil; André Vincente Esteves de Carvalho, Brazil; and Angela Londoño, Colombia Program faculty: Romina Contreras, Paraguay; Peter van de Kerkhof, the Netherlands; and Fernando Valenzuela, Chile
*Must be registered for the RADLA congress to attend.
NIH National Heart, Lung, and Blood Institute: Prevention of Cardiovascular Disease in Patients with Psoriasis and Psoriatic Arthritis: Bridging the Evidence to Practice Gap for Statins | Virtual
IPC’s Masterclass program is designed for early to mid-career dermatologists who are making treatment decisions and caring for patients with psoriasis. The program provides a comprehensive approach to psoriasis
management and equips attendees with the latest and most cutting-edge information available.
45 young dermatologists recently attended the 2021 IPC Psoriasis Masterclass – North Africa and Middle East virtual program. Over the five days of the course, IPC's world-renowned experts covered a variety of topics including the pathogenesis of psoriasis, new and emerging therapies and how to be an advocate for psoriasis patients.
Attendee Comments
“One of the most successful, well-organized, coherent classes I've attended since the beginning of the pandemic.”
“This masterclass provided proper understanding of psoriasis in depth, how to improve patient outcomes, and how to deal with different clinical scenarios even challenging cases.”
IPC Leadership
IPC welcomes new councilor, Satveer Mahil, PhD, MRCP
IPC Councilors play an important role in the work of IPC, serving in an advisory capacity and lending their global expertise on psoriasis research, treatment, and education. IPC would like to welcome Satveer Mahil, PhD, MRCP as our newest councilor!
IPC Chief Medical Officer Peter van de Kerkhof interviewed in Practical Dermatology
IPC's Chief Medical Officer Peter van de Kerkhof, MD, PhD, was featured in the Practical Dermatology January issue to discuss some of the most exciting research in psoriasis and insights on how COVID-19 affects the care of psoriasis patients.
Dermavant joins IPC as a new 2021 corporate member
Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company committed to fostering unprecedented change and unparalleled impact in immuno-dermatology.
“As a basic scientist, my interest is in helping to address these gaps in the field and to contribute to a better understanding of the pathophysiology behind psoriasis comorbidities and potentially personalized medicine. It’s my hope that the work we do in the lab helps psoriasis patients feel better and live longer, healthier, happier lives.”
Positive Data from PSOARING 3 long-term safety study
Dermavant announced positive safety and efficacy results from a planned interim analysis of PSOARING 3, its long-term, open-label safety study that, along with previously reported PSOARING 1 and PSOARING 2 pivotal efficacy trials, comprise Dermavant’s Phase 3 program for Tapinarof in adult patients with plaque psoriasis.
The National Psoriasis Foundation (NPF) offers Bridge Grants to support researchers who have submitted meritorious but unfunded K-type (career development) and R-type applications to the National Institutes of Health (NIH), or similar funding body, with a focus on psoriatic disease or related comorbidities. Due April 21, 2021.
IPC’s Masterclass program is designed for early to mid-career dermatologists who are making treatment decisions and caring for patients with psoriasis. The program provides a comprehensive approach to psoriasis
